Login Register Cart 0
Generic placeholder image

The International Journal of Gastroenterology and Hepatology Diseases

Editor-in-Chief

ISSN (Print): 2666-2906
ISSN (Online): 2666-2914

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Editorial

Advancements in GERD Treatment: Exploring Innovative Therapies

Author(s): Akshay Kumar Lunawat and Sarjana Raikwar*

Volume 3, 2024

Published on: 11 June, 2024

Article ID: e110624230920 Pages: 4

DOI: 10.2174/0126662906299185240520112218

Open Access Journals Promotions 2
[1]
Ravisankar P. A detailed analysis on acidity and ulcers in esophagus, gastric and duodenal ulcers and management. IOSR J Dent Med Sci 2016; 15(1): 94-114.
[2]
Tabibian JH. Digestive Problems Solved: A Patient’s Guide to Expert Insights and Solutions. Springer Nature 2023.
[http://dx.doi.org/10.1007/978-3-031-16317-3]
[3]
Alhejaili R, Alomainy A. The use of wearable technology in providing assistive solutions for mental well-being. Sensors 2023; 23(17): 7378.
[http://dx.doi.org/10.3390/s23177378] [PMID: 37687834]
[4]
Khan A, Kim A, Sanossian C, Francois F. Impact of obesity treatment on gastroesophageal reflux disease. World J Gastroenterol 2016; 22(4): 1627-38.
[http://dx.doi.org/10.3748/wjg.v22.i4.1627] [PMID: 26819528]
[5]
Chapelle N, Ben Ghezala I, Barkun A, Bardou M. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD). Expert Opin Pharmacother 2021; 22(2): 219-27.
[http://dx.doi.org/10.1080/14656566.2020.1817385] [PMID: 32893683]
[6]
Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor–related adverse effects. Ann N Y Acad Sci 2020; 1481(1): 43-58.
[http://dx.doi.org/10.1111/nyas.14428] [PMID: 32761834]
[7]
Tawam D, Baladi M, Jungsuwadee P, Earl G, Han J. The positive association between proton pump inhibitors and clostridium difficile infection. Innov Pharm 2021; 12(1): 21.
[http://dx.doi.org/10.24926/iip.v12i1.3439] [PMID: 34007671]
[8]
Almuzaini R, Almuzaini AS, Mohammed Alqifari A, et al. Assessment of awareness and knowledge of proton pump inhibitors among the general population in the Qassim region, Saudi Arabia. Cureus 2023; 15(10): e46749.
[http://dx.doi.org/10.7759/cureus.46749] [PMID: 38021654]
[9]
Drossman DA. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology 2016; 150(6): 1262-79.
[http://dx.doi.org/10.1053/j.gastro.2016.02.032]
[10]
Flores L, Krause C, Pokala B, et al. Novel therapies for gastroesophageal reflux disease. Curr Probl Surg 2019; 56(12): 100692.
[http://dx.doi.org/10.1016/j.cpsurg.2019.100692] [PMID: 31837718]
[11]
Bazerbachi F, Krishnan K, Abu Dayyeh BK. Endoscopic GERD therapy: A primer for the transoral incisionless fundoplication procedure. Gastrointest Endosc 2019; 90(3): 370-83.
[http://dx.doi.org/10.1016/j.gie.2019.05.028] [PMID: 31108091]
[12]
Dunn C, Bildzukewicz N, Lipham J. Magnetic sphincter augmentation for gastroesophageal reflux disease. Gastrointest Endosc Clin N Am 2020; 30(2): 325-42.
[http://dx.doi.org/10.1016/j.giec.2019.12.010] [PMID: 32146949]
[13]
Zhu X, Shen J. Anti-reflux mucosectomy (ARMS) for refractory gastroesophageal reflux disease. Eur J Med Res 2024; 29(1): 185.
[http://dx.doi.org/10.1186/s40001-024-01789-5] [PMID: 38500203]
[14]
Rodríguez de Santiago E, Sanchez-Vegazo CT, Peñas B, et al. Antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA) for gastroesophageal reflux disease: A systematic review and meta-analysis. Endosc Int Open 2021; 9(11): E1740-51.
[http://dx.doi.org/10.1055/a-1552-3239] [PMID: 34790538]
[15]
Jirapinyo P, Thompson CC. Endoscopic gastric plication for the treatment of GERD and underlying class I obesity. VideoGIE 2021; 6(2): 74-6.
[http://dx.doi.org/10.1016/j.vgie.2020.10.003] [PMID: 33884332]
[16]
Jirapinyo P, Thompson CC. Endoscopic gastric body plication for the treatment of obesity: Technical success and safety of a novel technique (with video). Gastrointest Endosc 2020; 91(6): 1388-94.
[http://dx.doi.org/10.1016/j.gie.2020.01.030] [PMID: 32001332]
[17]
Ganz RA, Edmundowicz SA, Taiganides PA, et al. Long-term outcomes of patients receiving a magnetic sphincter augmentation device for gastroesophageal reflux. Clin Gastroenterol Hepatol 2016; 14(5): 671-7.
[http://dx.doi.org/10.1016/j.cgh.2015.05.028] [PMID: 26044316]
[18]
Kushner BS, Awad MM, Mikami DJ, Chand BB, Wai CJ, Murayama KM. Endoscopic treatments for GERD. Ann N Y Acad Sci 2020; 1482(1): 121-9.
[http://dx.doi.org/10.1111/nyas.14511] [PMID: 33063344]
[19]
Rodríguez de Santiago E, Albéniz E, Estremera-Arevalo F, Teruel Sanchez-Vegazo C, Lorenzo-Zúñiga V. Endoscopic anti-reflux therapy for gastroesophageal reflux disease. World J Gastroenterol 2021; 27(39): 6601-14.
[http://dx.doi.org/10.3748/wjg.v27.i39.6601] [PMID: 34754155]
[20]
Bortolotti M. Magnetic challenge against gastroesophageal reflux. World J Gastroenterol 2021; 27(48): 8227-41.
[http://dx.doi.org/10.3748/wjg.v27.i48.8227] [PMID: 35068867]
[21]
Calabrese F, Poletti V, Auriemma F, et al. New perspectives in endoscopic treatment of gastroesophageal reflux disease. Diagnostics 2023; 13(12): 2057.
[http://dx.doi.org/10.3390/diagnostics13122057] [PMID: 37370952]
[22]
Lemperle G, Lemperle SM. Gastroesophageal reflux disease (GERD): An overview of current minimal-invasive treatment potentials. Am J Biomed Sci Res 2019; 2(6): 253-64.
[http://dx.doi.org/10.34297/AJBSR.2019.02.000619]
[23]
Savarino V, Marabotto E, Zentilin P, et al. Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. Expert Rev Clin Pharmacol 2020; 13(4): 437-49.
[http://dx.doi.org/10.1080/17512433.2020.1752664] [PMID: 32253948]
[24]
Hagymási K, Müllner K, Herszényi L, Tulassay Z. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2011; 12(6): 873-88.
[http://dx.doi.org/10.2217/pgs.11.4] [PMID: 21692617]
[25]
Khan WY. Pharmacogenomics in gastroenterology. Pharmacogenomics. Elsevier 2023; pp. 271-97.
[http://dx.doi.org/10.1016/B978-0-443-15336-5.00011-7]
[26]
Hungin APS, Scarpignato C, Keefer L, et al. Review article: Rethinking the “ladder” approach to reflux‐like symptom management in the era of PPI “resistance” ‐ a multidisciplinary perspective. Aliment Pharmacol Ther 2022; 55(12): 1492-500.
[http://dx.doi.org/10.1111/apt.16930] [PMID: 35460095]

Rights & Permissions Print Cite
Article Metrics
7
1
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy